Evaluating the Risk of Breast Cancer Recurrence and Metastasis After Adjuvant Tamoxifen Therapy by Integrating Polymorphisms in Cytochrome P450 Genes and Clinicopathological Characteristics
Tamoxifen (TAM) is the most commonly used adjuvant endocrine drug for hormone receptor-positive (HR+) breast cancer patients. However, how to accurately evaluate the risk of breast cancer recurrence and metastasis after adjuvant TAM therapy is still a major concern. In recent years, many studies hav...
Guardado en:
Autores principales: | Hui Pang, Guoqiang Zhang, Na Yan, Jidong Lang, Yuebin Liang, Xinyuan Xu, Yaowen Cui, Xueya Wu, Xianjun Li, Ming Shan, Xiaoqin Wang, Xiangzhi Meng, Jiaxiang Liu, Geng Tian, Li Cai, Dawei Yuan, Xin Wang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/5313a9c842734c44ad421fe0712d1041 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Breast Cancer and Tamoxifen: A Nigerian Perspective to Effective Personalised Therapy
por: Adehin A, et al.
Publicado: (2020) -
Design and Characterization of Maltoheptaose-<i>b</i>-Polystyrene Nanoparticles, as a Potential New Nanocarrier for Oral Delivery of Tamoxifen
por: Marcos Antonio Villetti, et al.
Publicado: (2021) -
Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
por: Butani D, et al.
Publicado: (2021) -
Centchroman versus Tamoxifen in the management of mastalgia: a randomized controlled clinical trial
por: S Khadka, et al.
Publicado: (2016) -
CYP2D6 polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study
por: Wickramage I, et al.
Publicado: (2017)